Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Rating of “Buy” by Brokerages

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have received an average recommendation of “Buy” from the nine analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $51.75.

A number of equities analysts recently commented on VERA shares. Evercore ISI upgraded shares of Vera Therapeutics to a “strong-buy” rating in a research note on Monday, September 16th. Cantor Fitzgerald reiterated an “overweight” rating and set a $107.00 target price on shares of Vera Therapeutics in a research note on Monday. Finally, JPMorgan Chase & Co. boosted their target price on shares of Vera Therapeutics from $62.00 to $72.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 3rd.

Vera Therapeutics Stock Performance

NASDAQ:VERA opened at $46.71 on Wednesday. The company has a fifty day simple moving average of $37.82 and a two-hundred day simple moving average of $39.02. The company has a market cap of $2.56 billion, a price-to-earnings ratio of -22.79 and a beta of 0.99. The company has a quick ratio of 21.43, a current ratio of 21.43 and a debt-to-equity ratio of 0.15. Vera Therapeutics has a 52 week low of $9.24 and a 52 week high of $50.78.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06). As a group, equities analysts anticipate that Vera Therapeutics will post -2.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, Director Beth C. Seidenberg sold 1,177 shares of the company’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $42.01, for a total value of $49,445.77. Following the completion of the transaction, the director now owns 160,376 shares in the company, valued at $6,737,395.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Marshall Fordyce sold 14,471 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $39.76, for a total value of $575,366.96. Following the completion of the sale, the chief executive officer now directly owns 322,667 shares of the company’s stock, valued at $12,829,239.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Beth C. Seidenberg sold 1,177 shares of the company’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $42.01, for a total transaction of $49,445.77. Following the completion of the sale, the director now directly owns 160,376 shares of the company’s stock, valued at $6,737,395.76. The disclosure for this sale can be found here. Insiders sold 31,273 shares of company stock worth $1,210,750 over the last 90 days. Corporate insiders own 21.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Public Employees Retirement Association of Colorado purchased a new position in Vera Therapeutics during the second quarter worth about $135,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Vera Therapeutics during the second quarter worth about $163,000. Ameritas Investment Partners Inc. raised its holdings in Vera Therapeutics by 20.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock worth $172,000 after purchasing an additional 688 shares in the last quarter. Cetera Advisors LLC purchased a new position in Vera Therapeutics during the first quarter worth about $235,000. Finally, Quarry LP purchased a new position in Vera Therapeutics during the second quarter worth about $235,000. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.